Prognosis of prosthetic valve infective endocarditis due to Streptococcus spp., a retrospective multi-site study to assess the impact of antibiotic treatment duration.
Infective endocarditis
Prosthetic valve
Streptococcus
Treatment duration
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
15 Nov 2023
15 Nov 2023
Historique:
received:
28
08
2023
accepted:
07
11
2023
medline:
15
11
2023
pubmed:
15
11
2023
entrez:
14
11
2023
Statut:
aheadofprint
Résumé
The duration of antibiotic treatment for prosthetic valve endocarditis caused by Streptococcus spp. is largely based on clinical observations and expert opinion rather than empirical studies. Here we assess the impact of a shorter antibiotic duration. To assess the impact of antibiotic treatment duration for streptococcal prosthetic valve endocarditis on 12-month mortality as well as subsequent morbidity resulting in additional cardiac surgical interventions, and rates of relapse and reinfection. This retrospective multisite (N= 3) study examines two decades of data on patients with streptococcal prosthetic valve endocarditis receiving either 4 or 6 weeks of antibiotics. Overall mortality, relapse, and reinfection rates were also assessed for the entire available follow-up period. The sample includes 121 patients (median age 72 years, IQR [53; 81]). The majority (74%, 89/121) received a ß-lactam antibiotic combined with aminoglycoside in 74% (89/121, median bi-therapy 5 days [1; 14]). Twenty-eight patients underwent surgery guided by ESC-guidelines (23%). The 12-month mortality rate was not significantly affected by antibiotic duration (4/40, 10% in the 4-week group vs 3/81, 3.7% in the 6-week group, p=0.34) or aminoglycoside usage (p=0.1). Similarly, there were no significant differences between the 2 treatment groups for secondary surgical procedures (7/40 vs 21/81, p=0.42), relapse or reinfection (1/40 vs 2/81 and 2/40 vs 5/81 respectively). Our study found no increased adverse outcomes associated with a 4-week antibiotic duration compared to the recommended 6-week regimen. Further randomized trials are needed to ascertain the optimal duration of treatment for streptococcal endocarditis.
Identifiants
pubmed: 37964043
doi: 10.1007/s10096-023-04705-7
pii: 10.1007/s10096-023-04705-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, Popescu BA, Prendergast B, Tornos P, Sadeghpour A et al (2019) Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J 40(39):3222–3232. https://doi.org/10.1093/eurheartj/ehz620
doi: 10.1093/eurheartj/ehz620
pubmed: 31504413
Chu VH, Cabell CH, Benjamin DK, Kuniholm EF, Fowler VG, Engemann J, Sexton DJ, Corey GR, Wang A (2004) Early predictors of in-hospital death in infective endocarditis. Circulation 109(14):1745–1749. https://doi.org/10.1161/01.CIR.0000124719.61827.7F
doi: 10.1161/01.CIR.0000124719.61827.7F
pubmed: 15037538
Kiefer T, Park L, Tribouilloy C, Cortes C, Casillo R, Chu V, Delahaye F, Durante-Mangoni E, Edathodu J, Falces C et al (2011) Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. JAMA 306(20). https://doi.org/10.1001/jama.2011.1701
Chirouze C, Cabell CH, Fowler VG, Khayat N, Olaison L, Miro JM, Habib G, Abrutyn E, Eykyn S, Corey GR et al (2004) Prognostic factors in 61 cases of Staphylococcus aureus prosthetic valve infective endocarditis from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 38(9):1323–1327. https://doi.org/10.1086/383035
doi: 10.1086/383035
pubmed: 15127349
Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B et al (2015) 2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36(44):3075–3128. https://doi.org/10.1093/eurheartj/ehv319
doi: 10.1093/eurheartj/ehv319
pubmed: 26320109
Marrie T, Cooper J, Costerton J (1987) Ultrastructure of cardiac bacterial vegetations on native valves with emphasis on alterations in bacterial morphology following antibiotic treatment. Can J Cardiol 6:275–280
Hoen B, Alla F, Selton-Suty C, Béguinot I, Bouvet A, Briançon S, Casalta J-P, Danchin N, Delahaye F, Etienne J et al (2002) Changing profile of infective endocarditisresults of a 1-year survey in France. JAMA 288(1):75–81. https://doi.org/10.1001/jama.288.1.75
doi: 10.1001/jama.288.1.75
pubmed: 12090865
Murdoch DR (2009) Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis–Prospective Cohort Study. Arch Intern Med 169(5):463. https://doi.org/10.1001/archinternmed.2008.603
doi: 10.1001/archinternmed.2008.603
pubmed: 19273776
pmcid: 3625651
Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, Strady C, Revest M, Vandenesch F, Bouvet A et al (2012) Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis 54(9):1230–1239. https://doi.org/10.1093/cid/cis199
doi: 10.1093/cid/cis199
pubmed: 22492317
Fihman V, Faury H, Moussafeur A, Huguet R, Galy A, Gallien S, Lim P, Lepeule R, Woerther P-L (2021) Blood cultures for the diagnosis of infective endocarditis: what is the benefit of prolonged incubation? J Clin Med 10(24):5824. https://doi.org/10.3390/jcm10245824
doi: 10.3390/jcm10245824
pubmed: 34945119
pmcid: 8705825
Cahill TJ, Prendergast BD (2016) Infective endocarditis. Lancet 387(10021):882–893. https://doi.org/10.1016/S0140-6736(15)00067-7
doi: 10.1016/S0140-6736(15)00067-7
pubmed: 26341945
Pilmis B, Lourtet-Hascoët J, Barraud O, Piau C, Isnard C, Hery-Arnaud G, Amara M, Merens A, Farfour E, Thomas E et al (2019) Be careful about MICs to amoxicillin for patients with Streptococci-related infective endocarditis. Int J Antimicrob Agents 53(6):850–854. https://doi.org/10.1016/j.ijantimicag.2019.03.002
doi: 10.1016/j.ijantimicag.2019.03.002
pubmed: 30851401
Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME et al (2015) Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 132(15):1435–1486. https://doi.org/10.1161/CIR.0000000000000296
doi: 10.1161/CIR.0000000000000296
pubmed: 26373316
Francioli P, Etienne J, Hoigné R, Thys J-P, Gerber A (1992) Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks: efficacy and outpatient treatment feasibility. JAMA 267(2):264–267. https://doi.org/10.1001/jama.1992.03480020074034
doi: 10.1001/jama.1992.03480020074034
pubmed: 1727524
Lefort A, Lortholary O, Casassus P, Selton-Suty C, Guillevin L, Mainardi J-L (2002) for the β-hemolytic streptococci infective endocarditis study group. comparison between adult endocarditis due to β-hemolytic streptococci (serogroups A, B, C, and G) and Streptococcus milleri: a multicenter study in France. Arch Intern Med 162(21):2450–2456. https://doi.org/10.1001/archinte.162.21.2450
doi: 10.1001/archinte.162.21.2450
pubmed: 12437404
McDonald EG, Aggrey G, Aslan AT, Casias M, Cortes-Penfield N, Dong MQD, Egbert S, Footer B, Isler B, King M, Maximos M (2023) Guidelines for diagnosis and management of infective endocarditis in adults: a WikiGuidelines group consensus statement. JAMA Network Open 6(7):e2326366. https://doi.org/10.1001/jamanetworkopen.2023.26366
doi: 10.1001/jamanetworkopen.2023.26366
pubmed: 37523190
Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, Bashore T, Corey GR (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30(4):633–638. https://doi.org/10.1086/313753
doi: 10.1086/313753
pubmed: 10770721
Mzabi A, Kernéis S, Richaud C, Podglajen I, Fernandez-Gerlinger M-P, Mainardi J-L (2016) Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non–severely ill patients. Clin Microbiol Infect 22(7):607–612. https://doi.org/10.1016/j.cmi.2016.04.003
doi: 10.1016/j.cmi.2016.04.003
pubmed: 27091094
Ly R, Compain F, Gaye B, Pontnau F, Bouchard M, Mainardi J-L, Iserin L, Lebeaux D, Ladouceur M (2021) Predictive factors of death associated with infective endocarditis in adult patients with congenital heart disease. Eur Heart J Acute Cardiovasc Care 10(3):320–328. https://doi.org/10.1177/2048872620901394
doi: 10.1177/2048872620901394
McGregor JC, Rich SE, Harris AD, Perencevich EN, Osih R, Lodise TP, Miller RR, Furuno JP (2007) A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 45(3):329–337. https://doi.org/10.1086/519283
doi: 10.1086/519283
pubmed: 17599310
Gould FK, Denning DW, Elliott TSJ, Foweraker J, Perry JD, Prendergast BD, Sandoe JAT, Spry MJ, Watkin RW (2012) Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 67(2):269–289. https://doi.org/10.1093/jac/dkr450
doi: 10.1093/jac/dkr450
pubmed: 22086858
Fernández Hidalgo N, Gharamti AA, Aznar ML, Almirante B, Yasmin M, Fortes CQ, Plesiat P, Doco-Lecompte T, Rizk H, Wray D et al (2020) Beta-hemolytic streptococcal infective endocarditis: characteristics and outcomes from a large, multinational cohort. Open Forum Infect Dis 7(5):ofaa120. https://doi.org/10.1093/ofid/ofaa120
doi: 10.1093/ofid/ofaa120
pubmed: 32462042
pmcid: 7240340
Chambers J, Sandoe J, Ray S, Prendergast B, Taggart D, Westaby S, Arden C, Grothier L, Wilson J, Campbell B et al (2014) The infective endocarditis team: recommendations from an international working group. Heart 100(7):524–527. https://doi.org/10.1136/heartjnl-2013-304354
doi: 10.1136/heartjnl-2013-304354
pubmed: 23990639
Isaza N, Shrestha NK, Gordon S, Pettersson GB, Unai S, Vega Brizneda M, Witten JC, Griffin BP, Xu B (2020) Contemporary outcomes of pulmonary valve endocarditis: a 16-year single centre experience. Heart Lung Circ 29(12):1799–1807. https://doi.org/10.1016/j.hlc.2020.04.015
doi: 10.1016/j.hlc.2020.04.015
pubmed: 32616369
Curran J, Lo J, Leung V, Brown K, Schwartz KL, Daneman N, Garber G, Wu JHC, Langford BJ (2022) Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis. Clin Microbiol Infect 28(4):479–490. https://doi.org/10.1016/j.cmi.2021.10.022
doi: 10.1016/j.cmi.2021.10.022
pubmed: 34775072